Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Bio-Path(US:BPTH) Newsfileยท2024-06-04 20:55Key Points - Bio-Path Holdings, Inc. (NASDAQ: BPTH) is currently advancing its Prexigebersen Phase 2 clinical trial [2] - The company has a diverse pipeline with numerous drug candidates under development [2] - Bio-Path has successfully raised $3.5 million in 2024, providing sufficient liquidity for its operations [2]